BioPorto A/S initiates a private placement of up to 25,000,000 new shares at market price. The Board of Directors has received advance indications for the full offering which is expected to raise proceeds of DKK 33.5 million.

Core Viewpoint - BioPorto A/S is initiating a private placement of up to 25,000,000 new shares at market price, aiming to raise approximately DKK 33.5 million to support its growth and clinical trials for its AKI diagnostic products [3][5]. Group 1: Offering Details - The private placement is part of a broader financing strategy to raise DKK 55 million (approximately USD 8.3 million) in the first half of 2025 [5]. - The subscription price for the new shares is set at DKK 1.3402, which reflects the closing price of BioPorto shares on April 11, 2025 [8]. - The offering will increase the share capital by up to 5.8% of BioPorto's registered share capital prior to the increase [8]. Group 2: Use of Proceeds - Proceeds from the offering will be allocated to finance clinical trials for FDA clearance of ProNephro AKI™ (NGAL) for adult use in the U.S., enhance sales and marketing for existing products, and cover general corporate purposes [5]. Group 3: Investor Interest - The company has received advanced indications from existing large shareholders, new professional investors, and management to subscribe for the full offering [6]. Group 4: Regulatory and Listing Information - The offering will be conducted as a directed issue to eligible institutional and professional investors in Denmark, exempt from the obligation to publish a prospectus [10]. - New shares are expected to be listed on Nasdaq Copenhagen A/S by April 30, 2025, subject to the offering not being withdrawn [12].